Although the dramatic increase in IL-6, IP-10, MCP-1, or IFN-γ was found in patients with COVID-19, who worsened even after tocilizumab administration, such an acute increase in these parameters were not observed after dexamethasone or dexamethasone followed by tocilizumab. The gene discussed is CCL2; the disease is COVID-19.